Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UGX02
- Development stage
- Preclinical
- Lead developer
- Suzhou Xingming Youjian Biotechnology
- Modality
- Gene Therapies
- Administration
- Ophthalmic
01
Overview
UGX02 is an investigational adeno-associated virus (AAV) vector-based gene therapy developed by Suzhou Xingming Youjian Biotechnology (U-Genex). It is designed for the treatment of retinal dystrophy and other degenerative retinal diseases, such as retinitis pigmentosa. The program is positioned as a potential best-in-class (BIC) therapy and is currently undergoing IND-enabling studies and investigator-initiated trials (IIT). UGX02 aims to address significant unmet medical needs in ophthalmology by utilizing AAV-mediated delivery to target the underlying causes of retinal degeneration and preserve or restore visual function.
Beyond the preview
Go deeper on UGX02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UGX02.